ACME Laboratories Ltd 2024 AR2
The report highlights ACME's 2023-2024 fiscal year, focusing on its transition towards a circular economy model to enhance sustainability. Key financial achievements include an 18.49% revenue growth and the successful launch of 44 new products. The company reached a significant milestone with the start of validation batches for its Active Pharmaceutical Ingredients (API) project and secured US FDA approval for its manufacturing site. Sustainability efforts are underscored by the Triple Bottom Line approach, featuring water recycling initiatives and a shift to HFA-based inhalers to reduce ozone depletion.
Company: ACME Laboratories Ltd
Sector: Manufacturing
Country: Bangladesh
Year: 2024
Type: AR2
Pages: 219
Back to company
ACME Laboratories Ltd
Annual Report
The report highlights ACME's 2023-2024 fiscal year, focusing on its transition towards a circular economy model to enhance sustainability. Key financial achievements include an 18.49% revenue growth and the successful launch of 44 new products. The company reached a significant milestone with the start of validation batches for its Active Pharmaceutical Ingredients (API) project and secured US FDA approval for its manufacturing site. Sustainability efforts are underscored by the Triple Bottom Line approach, featuring water recycling initiatives and a shift to HFA-based inhalers to reduce ozone depletion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees